| Prev Close | 1.40 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 1.03 / 1.72 |
| Avg Volume | 308.50K |
| Exchange | NASDAQ |
| Shares Outstanding | 69.05M |
| Market Cap | 99.43M |
| EPS | -0.60 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®
ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy
Alimera Sciences To Expand ILUVIEN® Indication In Europe For Posterior Uveitis
Signs license agreement with pSivida for posterior uveitis in Europe, the Middle East and Africa
Alimera Sciences Announces The Reimbursement Of ILUVIEN® In Italy
ILUVIEN is fully reimbursable as a hospital-administered therapy in Italy
Alimera Sciences Begins Selling ILUVIEN® In The Middle East
First DME patient in the region has received treatment
First Week of November 18th Options Trading For Alimera Sciences (ALIM)
Investors in Alimera Sciences, Inc. saw new options become available this week, for the November 18th expiration.
April 2017 Options Now Available For Alimera Sciences (ALIM)
Investors in Alimera Sciences, Inc. saw new options become available today, for the April 2017 expiration.
